{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:59:48Z","timestamp":1791993588766,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bcp.2021.114765","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:36:30Z","timestamp":1631702190000},"page":"114765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy"],"prefix":"10.1016","volume":"193","author":[{"given":"Valerie","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Min Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Souers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gewirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114765_b0005","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020 Jan;70(1):7\u201330.","DOI":"10.3322\/caac.21590"},{"issue":"6","key":"10.1016\/j.bcp.2021.114765_b0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2014.72","article-title":"Evolution of androgen receptor targeted therapy for advanced prostate cancer","volume":"11","author":"Wong","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114765_b0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1464-410X.2005.05798.x","article-title":"A retrospective study of the time to clinical endpoints for advanced prostate cancer","volume":"96","author":"Sharifi","year":"2005","journal-title":"BJU International."},{"issue":"2","key":"10.1016\/j.bcp.2021.114765_b0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.22571","article-title":"Androgen Deprivation Induces Senescence Characteristics in Prostate Cancer Cells In vitro and In vivo","volume":"73","author":"Ewald","year":"2013","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.bcp.2021.114765_b0030","doi-asserted-by":"crossref","first-page":"e68003","DOI":"10.1371\/journal.pone.0068003","article-title":"Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells. Agoulnik IU, editor","volume":"8","author":"Burton","year":"2013","journal-title":"PLoS ONE"},{"issue":"48","key":"10.1016\/j.bcp.2021.114765_b0035","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/onc.2015.41","article-title":"CCAAT\/Enhancer Binding Protein \u03b2 Controls Androgen Deprivation-Induced Senescence in Prostate Cancer Cells","volume":"34","author":"Barakat","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2021.114765_b0040","doi-asserted-by":"crossref","unstructured":"Pernicov\u00e1 Z, Slab\u00e1kov\u00e1 E, Kharaishvili G, Bouchal J, Kr\u00e1l M, Kunick\u00e1 Z, et al. Androgen Depletion Induces Senescence in Prostate Cancer Cells through Down-regulation of Skp2. Neoplasia. 2011 Jun;13(6):526-IN13.","DOI":"10.1593\/neo.11182"},{"key":"10.1016\/j.bcp.2021.114765_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jsbmb.2016.06.007","article-title":"Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer","volume":"165","author":"Kawata","year":"2017","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology."},{"key":"10.1016\/j.bcp.2021.114765_b0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00422-2","article-title":"Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells","author":"Pungsrinont","year":"2020","journal-title":"Cell & Bioscience [Internet]."},{"key":"10.1016\/j.bcp.2021.114765_b0055","doi-asserted-by":"crossref","unstructured":"Malaquin N, Vancayseele A, Gilbert S, Antenor-Habazac L, Olivier M-A, Ait Ali Brahem Z, et al. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. Cells. 2020 Jul 1;9(7):1593.","DOI":"10.3390\/cells9071593"},{"issue":"7","key":"10.1016\/j.bcp.2021.114765_b0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc3960","article-title":"Forging a signature of in vivo senescence","volume":"15","author":"Sharpless","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0065","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-Induced Senescence: An \u201cOld\u201d Friend Becomes the Enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers."},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0070","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular Senescence: Defining a Path Forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5483\/BMBRep.2019.52.1.294","article-title":"Cellular senescence: a promising strategy for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Reports."},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1096\/fba.2018-00084","article-title":"Stimulation of prostate cells by the senescence phenotype of epithelial and stromal cells: Implication for benign prostate hyperplasia","volume":"9","author":"Jiang","year":"2019","journal-title":"FASEB BioAdvances."},{"issue":"21","key":"10.1016\/j.bcp.2021.114765_b0085","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.211053698","article-title":"Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging","volume":"98","author":"Krtolica","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2021.114765_b0090","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B","volume":"18","author":"Sun","year":"2012","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2021.114765_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discovery."},{"key":"10.1016\/j.bcp.2021.114765_b0100","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer","author":"Duy","year":"2021","journal-title":"Discovery."},{"issue":"7","key":"10.1016\/j.bcp.2021.114765_b0105","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/ijc.25482","article-title":"Survivin and escaping in therapy-induced cellular senescence","volume":"128","author":"Wang","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2021.114765_b0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1667\/RR14202.1","article-title":"Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells","volume":"185","author":"Alotaibi","year":"2016","journal-title":"Radiat. Res."},{"issue":"7","key":"10.1016\/j.bcp.2021.114765_b0115","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/1078-0432.CCR-04-1462","article-title":"Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response","volume":"11","author":"Elmore","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"34","key":"10.1016\/j.bcp.2021.114765_b0120","doi-asserted-by":"crossref","first-page":"E5024","DOI":"10.1073\/pnas.1602379113","article-title":"Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence","volume":"113","author":"Patel","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2021.114765_b0125","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-04-1270","article-title":"Escape from Therapy-Induced Accelerated Cellular Senescence in p53-Null Lung Cancer Cells and in Human Lung Cancers","volume":"65","author":"Roberson","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114765_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bcp.2018.12.013","article-title":"Tumor cell escape from therapy-induced senescence","volume":"162","author":"Saleh","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114765_b0135","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.4161\/cc.28402","article-title":"Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers","volume":"13","author":"Chitikova","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2021.114765_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","author":"Fleury","year":"2019","journal-title":"Nature Communications [Internet]."},{"issue":"7686","key":"10.1016\/j.bcp.2021.114765_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0150","first-page":"220","article-title":"Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen- dependent cancer cells","volume":"6","author":"Tso","year":"2000","journal-title":"Cancer J."},{"issue":"12","key":"10.1016\/j.bcp.2021.114765_b0155","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to detect senescence-associated beta-galactosidase (SA-\u03b2gal) activity, a biomarker of senescent cells in culture and in vivo","volume":"4","author":"Debacq-Chainiaux","year":"2009","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.bcp.2021.114765_b0160","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1021\/acs.analchem.7b04828","article-title":"High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity","volume":"90","author":"Huang","year":"2018","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0165","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1039\/D0AN01769H","article-title":"Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population","volume":"146","author":"Murray","year":"2021","journal-title":"Analyst."},{"issue":"15","key":"10.1016\/j.bcp.2021.114765_b0170","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1200\/JCO.2018.78.0619","article-title":"Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Morris","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2021.114765_b0175","doi-asserted-by":"crossref","unstructured":"Nevedomskaya E, Baumgart SJ, Haendler B. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci [Internet]. 2018 May 4 [cited 2018 Jul 10];19(5). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5983695\/.","DOI":"10.3390\/ijms19051359"},{"key":"10.1016\/j.bcp.2021.114765_b0180","doi-asserted-by":"crossref","unstructured":"Anker JF, Mok H, Naseem AF, Thumbikat P, Abdulkadir SA. A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp [Internet]. 2018 Mar 6 [cited 2018 Jul 10];(133). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5931443\/.","DOI":"10.3791\/57301-v"},{"issue":"24","key":"10.1016\/j.bcp.2021.114765_b0185","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-05-3441","article-title":"Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell Line","volume":"65","author":"Watson","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114765_b0190","doi-asserted-by":"crossref","unstructured":"Saleh T, Carpenter VJ, Tyutyunyk\u2010Massey L, Murray G, Leverson JD, Souers AJ, et al. Clearance of therapy\u2010induced senescent tumor cells by the senolytic ABT\u2010263 via interference with BCL\u2010X L \u2010BAX Interaction. Molecular Oncology [Internet]. 2020 Jul 11 [cited 2020 Jul 15]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/1878-0261.12761.","DOI":"10.1002\/1878-0261.12761"},{"issue":"49","key":"10.1016\/j.bcp.2021.114765_b0195","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41391-017-0013-x","article-title":"Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model","volume":"21","author":"Shen","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"10.1016\/j.bcp.2021.114765_b0205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euf.2016.11.013","article-title":"Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor","volume":"2","author":"Tilki","year":"2016","journal-title":"European Urology Focus."},{"issue":"39","key":"10.1016\/j.bcp.2021.114765_b0210","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0215","first-page":"20","article-title":"Castration-resistance prostate cancer: what is in the pipeline?","volume":"70","author":"Nunzio","year":"2018","journal-title":"Minerva Urol. Nefrol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114765_b0220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.bcp.2021.114765_b0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-020-0564-6","article-title":"BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer","author":"Shahbandi","year":"2020","journal-title":"Cell Death & Differentiation [Internet]."},{"issue":"11","key":"10.1016\/j.bcp.2021.114765_b0230","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.18632\/aging.101100","article-title":"Discovery of piperlongumine as a potential novel lead for the development of senolytic agents","volume":"8","author":"Wang","year":"2016","journal-title":"Aging."},{"issue":"14","key":"10.1016\/j.bcp.2021.114765_b0235","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1016\/j.bmc.2018.06.013","article-title":"Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation","volume":"26","author":"Liu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2021.114765_b0240","doi-asserted-by":"crossref","first-page":"771","DOI":"10.18632\/aging.101787","article-title":"The curcumin analog EF24 is a novel senolytic agent","volume":"11","author":"Li","year":"2019","journal-title":"Aging."},{"key":"10.1016\/j.bcp.2021.114765_b0245","doi-asserted-by":"crossref","unstructured":"Wakita M, Takahashi A, Sano O, Loo TM, Imai Y, Narukawa M, et al. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. Nature Communications [Internet]. 2020 Dec [cited 2020 Jul 6];11(1). Available from: http:\/\/www.nature.com\/articles\/s41467-020-15719-6.","DOI":"10.1038\/s41467-020-15719-6"},{"issue":"7501","key":"10.1016\/j.bcp.2021.114765_b0250","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature13193","article-title":"The role of senescent cells in ageing","volume":"509","author":"van Deursen","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41556-018-0249-2","article-title":"The dynamic nature of senescence in cancer","volume":"21","author":"Lee","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114765_b0260","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.253203","article-title":"Nuclear localization of p65 reverses therapy-induced senescence","volume":"134","author":"Salunkhe","year":"2021","journal-title":"J. Cell Sci."},{"issue":"10","key":"10.1016\/j.bcp.2021.114765_b0265","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","article-title":"Senescent Cells in Cancer Therapy: Friends or Foes?","volume":"6","author":"Wang","year":"2020","journal-title":"Trends in Cancer."},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol."},{"issue":"26","key":"10.1016\/j.bcp.2021.114765_b0275","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","article-title":"SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells","volume":"31","author":"Canino","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2021.114765_b0280","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-017-0172-3","article-title":"Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence\/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line","author":"Ortiz-Montero","year":"2017","journal-title":"Cell Communication and Signaling [Internet]."},{"issue":"6","key":"10.1016\/j.bcp.2021.114765_b0285","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","article-title":"Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy","volume":"79","author":"Saleh","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114765_b0290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2019.08.004","article-title":"Connecting cancer relapse with senescence","volume":"463","author":"Pluquet","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0295","doi-asserted-by":"crossref","first-page":"409","DOI":"10.18632\/oncotarget.2774","article-title":"Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1","volume":"6","author":"Jonch\u00e8re","year":"2015","journal-title":"Oncotarget."},{"issue":"10","key":"10.1016\/j.bcp.2021.114765_b0300","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20130783","article-title":"p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells","volume":"210","author":"Iannello","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2021.114765_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.03.008","article-title":"Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer","volume":"181","author":"Ruscetti","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0310","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/cancers13040723","article-title":"Senolytics for Cancer Therapy: Is All that Glitters Really Gold?","volume":"13","author":"Carpenter","year":"2021","journal-title":"Cancers."},{"key":"10.1016\/j.bcp.2021.114765_b0315","first-page":"1876","article-title":"DNA Damage Is Able to Induce Senescence in Tumor Cells in Vitro and in Vivo 1","volume":"62","author":"te Poele","year":"2002","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2021.114765_b0320","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210079","article-title":"Expression of therapy-induced senescence markers in breast cancer samples upon incomplete response to neoadjuvant chemotherapy","volume":"41","author":"Saleh","year":"2021","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2021.114765_b0325","article-title":"Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy","volume":"12","author":"Blute","year":"2017","journal-title":"Kyprianou N, editor. PLOS ONE."},{"issue":"2","key":"10.1016\/j.bcp.2021.114765_b0330","article-title":"Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications. Biochimica et Biophysica Acta (BBA) - Reviews on","volume":"1874","author":"Carpenter","year":"2020","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2021.114765_b0335","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.cub.2017.07.033","article-title":"Unmasking Transcriptional Heterogeneity in Senescent Cells","volume":"27","author":"Hernandez-Segura","year":"2017","journal-title":"Curr. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114765_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. Downward J, editor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PLoS Biol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114765_b0345","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cells8121501","article-title":"Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents","volume":"8","author":"Bojko","year":"2019","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.bcp.2021.114765_b0350","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.celrep.2017.09.085","article-title":"High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer","volume":"21","author":"Wang","year":"2017","journal-title":"Cell Reports."},{"issue":"7777","key":"10.1016\/j.bcp.2021.114765_b0355","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"Wang","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm.4010","article-title":"Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice","volume":"22","author":"Chang","year":"2016","journal-title":"Nat. Med."},{"issue":"7372","key":"10.1016\/j.bcp.2021.114765_b0365","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10600","article-title":"Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders","volume":"479","author":"Baker","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2021.114765_b0370","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1535-7163.MCT-11-0693","article-title":"Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models","volume":"11","author":"Wong","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"279","key":"10.1016\/j.bcp.2021.114765_b0375","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114765_b0380","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.009","article-title":"Phase I\/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours","volume":"30","author":"Corcoran","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2021.114765_b0385","doi-asserted-by":"crossref","unstructured":"Harrison CN, Garcia JS, Mesa RA, Somervaille TC, Komrokji RS, Pemmaraju N, et al. Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. Blood. 2019 Nov 13;134(Supplement_1):671\u2013671.","DOI":"10.1182\/blood-2019-130158"},{"issue":"1","key":"10.1016\/j.bcp.2021.114765_b0390","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114765_b0395","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2021.114765_b0400","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.04.045","article-title":"Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic","volume":"323","author":"Galiana","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2021.114765_b0405","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13142","article-title":"Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity","author":"Gonz\u00e1lez-Gualda","year":"2020","journal-title":"Aging Cell [Internet]."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:12:02Z","timestamp":1762096322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":81,"alternative-id":["S0006295221003816"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114765","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114765"}}